COMMITTED TO ENGINEERING TRANSFORMATIVE THERAPIES FOR AUTOIMMUNE DISEASES

STRIVING TO REDEFINE OUTCOMES FOR TENS OF THOUSANDS OF PATIENTS

DEVELOPING INNOVATIONS DESIGNED TO GIVE PATIENTS CONTROL OVER THEIR HEALTH

Our Vision

Normal lives for patients with autoimmune diseases

Therapeutic Focus

Autoimmune diseases occur when the immune system is unable to distinguish between harmful pathogens and the body’s own healthy tissues. These diseases target both specific organs and broader bodily systems.

Pipeline

Pre-clinical

Phase 1

Phase 2

Phase 3

Myasthenia Gravis

Thyroid Eye Disease

Warm Autoimmune Hemolytic Anemia

Immunovant’s investigational product candidate, IMVT-1401 (formerly known as RVT-1401), is a novel, fully human monoclonal antibody targeting the neonatal Fc receptor (FcRn). We believe that this product has the potential to address a variety of IgG-mediated autoimmune diseases as a subcutaneous injection.

Read More